Literature DB >> 8420378

Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy.

A Scheider1, J E Nasemann, O E Lund.   

Abstract

We examined 19 patients (41 +/- 7.5 years old) with central serous chorioretinopathy and symptoms that ranged from one day to 24 months. Fluorescein and indocyanine green angiographies were performed with a scanning laser ophthalmoscope. Focal exudation was found in all patients with fluorescein and in 15 patients (79%) with indocyanine green. We found a more widespread exudation of indocyanine green into the choroid around the focal hyperfluorescent spot in seven patients (37%). Perfusion with fluorescein was delayed in the area of focal exudation in two patients (11%) and with indocyanine green in 12 patients (63%). Exudation of both dyes stopped with clinical improvement, whereas the perfusion deficits remained unchanged. These results further indicate that central serous chorioretinopathy is primarily a choroidal disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8420378     DOI: 10.1016/s0002-9394(14)73524-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  49 in total

Review 1.  Central serous retinopathy associated with adrenocorticotrophic hormone therapy. A case report and a hypothesis.

Authors:  E Zamir
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

Review 2.  Indocyanine green angiography.

Authors:  S L Owens
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

3.  Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes.

Authors:  S H Karakus; B Basarir; E Y Pinarci; E U Kirandi; A Demirok
Journal:  Eye (Lond)       Date:  2013-03-22       Impact factor: 3.775

4.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

5.  Axial length in unilateral idiopathic central serous chorioretinopathy.

Authors:  Hoseok Moon; Dae Yeong Lee; Dong Heun Nam
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

6.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

7.  Central serous chorioretinopathy due to tadalafil use.

Authors:  Fatih Mehmet Türkcü; Harun Yüksel; Alparslan Şahin; Mehmet Murat; Yaşar Bozkurt; Ihsan Çaça
Journal:  Int Ophthalmol       Date:  2012-10-14       Impact factor: 2.031

8.  Smokestack leak in central serous chorioretinopathy.

Authors:  Dhiren Bujarborua; Pran N Nagpal; Manab Deka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-10-15       Impact factor: 3.117

9.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

10.  Features of abnormal choroidal circulation in central serous chorioretinopathy.

Authors:  N Kitaya; T Nagaoka; T Hikichi; R Sugawara; K Fukui; S Ishiko; A Yoshida
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.